Rizatriptan 5 mg Orodispersible Tablets

Each orodispersible tablet contains 7.265 mg of rizatriptan benzoate (corresponding to 5 mg of the rizatriptan).

Excipient(s) with known effect: Each tablet contains 1.0 mg of aspartame (E 951) and 45.810 mg of mannitol (E 421).

For the full list of excipients, see section 6.1.

Orodispersible tablet

Rizatriptan 5 mg orodispersible tablet are white, round, flat faced beveled edge tablets, debossed with “HP” on one side and “238” on other side.

Acute treatment of the headache phase of migraine attacks with or without aura in adults.

Method of administration

Rizatriptan should not be used prophylactically.

Rizatriptan need not be taken with liquid.

Patients should be instructed on how to remove the blister pack from the bag. The blister pack is to be opened with dry hands and the melt tablet is to be kept on the tongue, where it dissolves and to be swallowed with the saliva.

Rizatriptan is also available in tablet formulation.

The orodispersible tablet can be used in situations in which liquids are not available, or to avoid nausea and vomiting that may accompany with the ingestion of tablets with liquids.

Posology

Adults (18 years and older)

The recommended dose is 10 mg.

Redosing: doses should be separated by at least two hours. No more than two doses should be taken in any 24 hour period.

• For headache recurrence within 24 hours: If headache returns after relief of the initial attack, one further dose may be taken, the above dosing limits should be observed.

• After non-response: The effectiveness of a second dose for treatment of the same attack when the initial dose is ineffective has not been studied in controlled clinical trials. Therefore, if a patient does not respond to the first dose, a second dose should not be taken for the same attack

Clinical studies have shown that patients who do not respond to treatment of an attack are still likely to respond to treatment for subsequent attacks.

Some patients should receive the lower (5 mg) dose of Rizatriptan orodispersible tablets, in particular the following patient groups:

• patients on propranolol. Administration of Rizatriptan should be separated by at least two hours from administration of propranolol (see section 4.5);

• patients with mild or moderate renal impairment;

• patients with mild to moderate hepatic impairment.

Doses should be separated by at least two hours; no more than two doses should be taken in any 24-hour period.

Paediatric population

The safety and efficacy of rizatriptan in children and adolescents up to 18 years have not yet been established.

Currently available data are described in section 5.1 and 5.2 but no recommendation on a posology can be made.

Elderly

The safety and effectiveness of Rizatriptan in patients older than 65 years has not been systematically evaluated.

• Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.

• Concurrent administration of monoamine oxidase (MAO) inhibitors or use within two weeks after discontinuation of treatment with an MAOI (see section 4.5).

• Patients with severe hepatic or severe renal insufficiency.

• Patients with a previous cerebrovascular accident (CVA) or transient ischemic attack (TIA).

• Moderately severe or severe hypertension, or untreated mild hypertension.

• Established coronary artery disease, including ischemic heart disease (angina, through myocardial infarction, or documented silent ischemia), signs and symptoms of ischemic heart disease or Prinzmetal angina.

• Peripheral vascular disease.

• Concomitant use of rizatriptan and ergotamine, ergot derivatives (including methysergide) or other 5-HT 1B / 1D receptor agonists (see section 4.5).

Rizatriptan should only be administered to patients in whom a clear diagnosis of migraine has been established and should not be administered to patients with basilar or hemiplegic migraine.

Rizatriptan should not be used to treat 'atypical' headaches, i.e. those that might be associated with potentially serious medical conditions (eg, CVA, ruptured aneurysm) in which cerebrovascular vasoconstriction could be harmful.

Rizatriptan can be associated with transient symptoms, including chest pain and tightness which may be intense and involve the throat (see section 4.8). Where such symptoms are thought to indicate ischemic heart disease, no further dose should be taken and appropriate evaluation must be carried out.

As with other 5-HT _{1B / 1D} receptor agonists, rizatriptan should not be given, without prior evaluation, to patients in whom unrecognized cardiac disease is likely or to patients at risk for coronary artery disease (CAD) (eg patients with hypertension, diabetics, smokers or users of nicotine substitution therapy, men over 40 years, postmenopausal women, patients with bundle branch block and those with a strong family history for CAD). Cardiac evaluations may not identify every patient who has cardiac disease and, in very rare cases serious cardiac events have occurred in patients without underlying cardiovascular disease when 5-HT₁ agonists have been administered. Those in whom CAD is established should not be given Rizatriptan (see section 4.3).

5-HT _{1B / 1D} receptor agonists have been associated with coronary vasospasm. In rare cases, myocardial ischaemia or infarction have been reported with 5-HT_1B/1D receptor agonists including rizatriptan. (see section 4.8).

Other 5-HT _{1B / 1D} agonists (eg, sumatriptan) should not be used concomitantly with rizatriptan (see section 4.5).

It is advised to wait at least six hours following use of rizatriptan before administering ergotamine-type medication (e.g. ergotamine, dihydroergotamine or methysergide). At least 24 hours should elapse after the administration of an ergotamine-containing preparation before rizatriptan is given. Although additive vasospastic effects were not observed in a clinical pharmacology study in which 16 healthy males received oral rizatriptan and parenteral ergotamine, such additive effects are theoretically possible (see section 4.3).

Serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) has been reported following concomitant treatment with triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin-noradrenaline reuptake inhibitors (SNRIs). These reactions can be severe. If concomitant treatment with rizatriptan and an SSRI or SNRI is clinically warranted, appropriate observation of the patient is advised, particularly during treatment initiation, with dose increases, or with addition of another serotonergic medication (see section 4.5).

Undesirable effects may be more common during concomitant use of triptans (5-HT _{1B / 1D} agonists) and herbal preparations containing St. John's wort (Hypericum perforatum).

Angioedema (e.g. facial oedema, tongue swelling and pharyngeal oedema) may occur in patients treated with triptans, among which is rizatriptan. If angioedema of the tongue or pharynx occurs, the patient should be placed under medical supervision until symptoms have resolved. Treatment should promptly be discontinued and replaced by an agent belonging to another class of drugs.

Phenylketonurics: Phenylketonuric patients should be informed that phenylalanine may be harmful. Rizatriptan contains aspartame (which contains phenylalanine). Each 5 mg orodispersible tablet contains 1.0 mg aspartame.

Laxative: Rizatriptan 5 mg orodispersible tablet contains 45.810 of mannitol (E 421) which may have a mild laxative effect.

The potential for interaction should be considered when rizatriptan is administered to patients taking CYP 2D6 substrates (see section 4.5).

Medication overuse headache (MOH)

Prolonged use of any painkiller for headaches can make them worse. If this situation is experienced or suspected, medical advice should be obtained and treatment should be discontinued. The diagnosis of MOH should be suspected in patients who have frequent or daily headaches despite (or because of) the regular use of headache medications.

Ergotamine, ergot derivatives (including methysergide), other 5-HT _{1B / 1D} receptor agonists:

Due to an additive effect, the concomitant use of rizatriptan and ergotamine, ergot derivatives (including methysergide), or other 5-HT _{1B / 1D} receptor agonists (such as sumatriptan, zolmitriptan, naratriptan) increase the risk of coronary artery vasoconstriction and hypertensive effects. This combination is contraindicated (see section 4.3).

Monoamine oxidase inhibitors:

Rizatriptan is principally metabolized via monoamine oxidase 'A' subtype (MAO-A). Plasma concentrations of rizatriptan and its active N-monodesmethyl metabolite were elevated by concomitant administration of a selective, reversible MAO-A inhibitor. Similar or greater effects are expected with non-selective, reversible (eg linezolid) and irreversible MAO inhibitors. Due to a risk of coronary artery vasoconstriction and hypertensive episodes, administration of rizatriptan to patients taking inhibitors of MAO is contraindicated (see section 4.3).

Beta-blockers:

Plasma concentrations of rizatriptan may be increased by coadministration of propranolol. This increase is probably due to a first-pass metabolic interaction between the two drugs, since MAO-A plays a role in the metabolism of both rizatriptan and propranolol. This interaction leads to a mean increase in AUC and C_max by 70-80%. In patients receiving propranolol, the 5 mg dose of Rizatriptan should be used (see section 4.2).

In a drug interaction study, nadolol and metoprolol did not alter plasma concentrations of rizatriptan.

Selective Serotonin Reuptake Inhibitors (SSRIs) / Serotonin Norepinephrine Reuptake Inhibitors

(SNRIs) and Serotonin Syndrome:

There have been reports describing patients with symptoms compatible with serotonin syndrome (including altered mental health status, autonomic instability and neuromuscular abnormalities) following the use of selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) and triptans (see section 4.4).

In vitro studies indicate that rizatriptan inhibits cytochrome P450 2D6 (CYP 2D6). Clinical interaction data are not available. The potential for interaction should be considered when rizatriptan is administered to patients taking CYP 2D6 substrates.

Fertility

Effects on human fertility have not been investigated. Animal studies only revealed minimal effects on fertility at plasma concentrations far in excess of human therapeutic concentrations (more than 500-fold).

Pregnancy

The safety of rizatriptan for use in human pregnancy has not been established. Animal studies do not indicate harmful effects at dose levels that exceed therapeutic dose levels with respect to the development of the embryo or foetus, or the course of gestation, parturition and post-natal development.

Because animal reproductive and developmental studies are not always predictive of human response, Rizatriptan should be used during pregnancy only if clearly needed.

Breastfeeding

Studies in rats indicated that a very high milk transfer of rizatriptan occurred. Transient, very slight decreases in pre-weaning pup body weights were observed only when the mother's systemic exposure was well in excess of the maximum exposure level for humans. No data exist in humans. Therefore, caution should be exercised when administering rizatriptan to women who are breast feeding. Infant exposure should be minimised by avoiding breast feeding for 24 hours after treatment.

Migraine or treatment with Rizatriptan may cause somnolence in some patients. Dizziness has also been reported in some patients receiving rizatriptan. Patients should, therefore, evaluate their ability to perform complex tasks during migraine attacks and after administration of rizatriptan orodispersible tablets.

Rizatriptan (as the tablet and oral lyophilisate formulation) was evaluated in 8630 adult patients for up to one year in controlled clinical studies. The most common side effects evaluated in clinical trials were dizziness, somnolence and asthenia/fatigue. The following side effects have been evaluated in clinical trials and/or reported in post-marketing experience:

Very common (≥ 1/10); Common (≥1/100, <1/10); Uncommon (≥ 1/1000, <1/100); Rare (≥ 1 / 10,000, <1/1000); Very rare (≤ 1 / 10,000); Not known (cannot be estimated from the available data)

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

Rizatriptan 40 mg (administered as a single dose or as two doses with two-hour interdose interval) was generally well tolerated in over 300 adult; dizziness and somnolence were the most common drug-related adverse effects.

In a clinical pharmacology study in which 12 adult subjects received rizatriptan, at a total cumulative dose of 80 mg (given within four hours), two subjects experienced syncope and/or bradycardia. One subject, a female aged 29 years, developed vomiting, bradycardia, and dizziness beginning three hours after receiving a total of 80 mg rizatriptan (administered over two hours). A third degree AV block, responsive to atropine, was observed an hour after the onset of the other symptoms. The second subject, a 25-year-old male, experienced transient dizziness, syncope, incontinence, and a 5-second systolic pause (on ECG monitor) immediately after a painful venipuncture. The venipuncture occurred two hours after the subject had received a total of 80 mg rizatriptan (administered over four hours).

In addition, based on the pharmacology of rizatriptan, hypertension or other more serious cardiovascular symptoms could occur after overdosage. Gastro-intestinal decontamination, (e.g. gastric lavage followed by activated charcoal) should be considered in patients suspected of an overdose with rizatriptan. Clinical and electrocardiographic monitoring should be continued for at least 12 hours, even if clinical symptoms are not observed.

The effects of haemo- or peritoneal dialysis on serum concentrations of rizatriptan are unknown.

Pharmacotherapeutic group: ATC-code: antimigraine preparations, selective serotonin (5-HT₁) agonists, N02C C04.

Mechanism of action: Selective serotonin (5-HT _{1B / 1D}) agonists

Rizatriptan binds selectively and with high affinity to human 5-HT_1B and 5-HT_1D receptors and has little or no effect or pharmacological activity at 5-HT₂, 5-HT₃; adrenergic alpha₁, alpha₂ or beta; D₁, D₂ dopaminergic, histaminic H₁, muscarinic or benzodiazepine receptors.

The therapeutic activity of rizatriptan in treating migraine headache may be attributed to its agonist effects at 5-HT_1B and 5-HT_1D receptors on the extracerebral intracranial blood vessels that are thought to become dilated during an attack and on the trigeminal sensory nerves that innervate them. Activation of these 5-HT_1B and 5-HT_1D receptors may result in constriction of pain-producing intracranial blood vessels and inhibition of neuropeptide release that leads to decreased inflammation in sensitive tissues and reduced central trigeminal pain signal transmission.

Pharmacodynamic effects

Adults

The efficacy of rizatriptan orodispersible tablets in the acute treatment of migraine attacks was established in two multicentre randomized, placebo-controlled trials, that were similar in design to the trials of rizatriptan tablets. In one study (n = 311), by two hours post-dosing, relief rates in patients treated with rizatriptan orodispersible tablets were approximately 66% for rizatriptan 5 mg and 10 mg, compared to 47% in the placebo group. In a larger study (n = 547), by 2 hours post-dosing, relief rates were 59% in patients treated with rizatriptan orodispersible tablets 5 mg, and 74% after 10 mg, compared to 28% in the placebo group. Rizatriptan orodispersible tablets also relived the disability, nausea, photophobia, and phonophobia which accompanied the migraine episodes. A significant effect on pain relief was observed as early as 30 minutes post-dosing in one of the two clinical trials for the 10 mg dose (see section 5.2).

Based on studies with the oral tablet, rizatriptan orodispersible tablet remains effective in treating menstrual migraine, migraine i.e. migraine that occurs within 3 days before or after the onset of menses.

Paediatric patients

Youth (12-17 years of age)

The efficacy of rizatriptan orodispersible tablets in paediatric patients (12 to17 years of age) was evaluated in a multicentre randomized, double-blind, placebo-controlled, parallel group study (N=570). The patient population was required to be historically non-responsive to NSAIDs and acetaminophen therapy. Patients with a qualifying migraine headache were initially administered placebo or rizatriptan within 30 minutes of onset. Following the 15 minutes placebo run-in, subjects who do not respond to placebo then treated a single migraine attack with placebo or rizatriptan. Using a weight-based dosing strategy patients 20 kg to <40 kg received 5 mg rizatriptan and patients≥ 40 kg received 10 mg rizatriptan.

In this enriched population study, a difference of 9% between active treatment and placebo was observed for the primary efficacy endpoint of pain freedom (reduction from moderate or severe pain to no pain) 2 hours after treatment (31% under rizatriptan vs. 22% for placebo (p = 0.025)). No significant difference for the secondary endpoint of pain relief (reduction from moderate or severe pain to mild or no pain) was found.

Children (6-11 years of age)

The efficacy of rizatriptan orodispersible tablet was also evaluated in paediatric patients aged 6-11 years of age in the same acute placebo-controlled clinical trial (n = 200). The percentage of patients achieving pain freedom 2 hours after treatment was not statistically significantly different in patients who received rizatriptan orodispersible 5 and 10 mg, compared with those who received placebo (39.8% vs. 30.4%, p=0.269).

Rizatriptan orodispersible tablets enables migraine patients to treat their migraine attacks without having to swallow liquids. This may allow patients to administer their medication earlier, for example, when liquids are not available and to avoid possible worsening of GI symptoms by swallowing liquids.

Absorption

Rizatriptan is rapidly and completely absorbed following oral administration. The mean oral bioavailability availability of orodispersible tablet is approximately 40-45%, and mean peak plasma concentration (C_max) are reached in approximately 1.58 hours (T_max). The time required to maximum plasma concentration following administration of rizatriptan as orodispersible tablet is delayed by 30-60 minutes relative to the tablet.

Effect of Food: The effect of food on the absorption of rizatriptan from the orodispersible tablet has not been studied. For the rizatriptan tablets, T_max is delayed approximately 1 hour when the tablets are administered in the fed state. A further delay in the absorption of rizatriptan may occur when orodispersible tablet is administered after meals.

Distribution

Rizatriptan is minimally bound (14%) to plasma proteins. The volume of distribution is approximately 140 litres in male subjects, and 110 litres in female subjects.

Biotransformation

The primary route of rizatriptan metabolism is via oxidative deamination by monoamine oxidase-A (MAO-A) to the indole acetic acid metabolite, which is not pharmacologically active. N monodesmethyl-rizatriptan, a metabolite with activity similar to that of the parent compound at the 5-HT_1B/1D receptors is formed to a small minor degree, but does not contribute significantly to the pharmacodynamic activity of rizatriptan. Plasma concentrations of N-monodesmethyl-rizatriptan are approximately 14% of those of parent compound and it is eliminated at a similar rate. Other minor metabolites include the N-oxide,the 6-hydroxy compound, and the sulphate conjugate of the 6-hydroxy metabolite. None of these minor metabolites is pharmacologically active. Following oral administration of ¹⁴C-labeled rizatriptan, rizatriptan accounts for about 17% of the circulating plasma radioactivity.

Elimination

Following intravenous administration, AUC in men increases proportionally and in women near-proportionally with the dose over a dose range of 10-60 µg/kg. Following oral administration, AUC increases near- proportionally with the dose over a dose range of 2.5-10 mg. The plasma half-life of rizatriptan males and females averages 2-3 hours. The plasma clearance of rizatriptan averages about 1000-1500 ml / min in males and approximately 900-1100 ml / min in females; about 20-30% of this is renal clearance. Following an oral dose of ¹⁴C-labeled rizatriptan, about 80% of the radio-activity is excreted in urine, and about 10% of the dose is excreted in faeces. This shows that the metabolites are excreted primarily via the kidneys.

Consistant with its first pass metabolism, approximately 14% of an oral dose is excreted in urine as unchanged rizatriptan, while 51% is excreted as indole acetic acid metabolite. No more than 1% is excreted in urine as the active N-monodesmethyl metabolite.

If rizatriptan is administered according to the maximum dosage regimen, no drug accumulation in the plasma occurs from day to day.

Characteristics in patients:

The following data are based on studies with the oral tablet formulation.

Patients with a migraine attack:

A migraine attack has no effect on the pharmacokinetics of rizatriptan.

Gender:

The AUC of rizatriptan (10 mg orally) was about 25% lower in males as compared to females, C_max was 11% lower, and T_max occurred at approximately the same time. This apparent pharmacokinetic difference was of no clinical significance.

Elderly:

The plasma concentrations of rizatriptan observed in elderly subjects (age 65-77 years), after tablet administration were similar to those observed in young people.

Paediatric patients:

A pharmacokinetics study of rizatriptan (as melt tablet) was conducted in paediatric migraineurs 6-17 years of age. The mean exposures following a single dose administration of 5 mg rizatriptan melt tablet to paediatric patients weighing 20-39 kg, or 10 mg rizatriptan melt tablet to paediatric patients weighing ≥ 40 kg, were respectively 15% lower and 17% higher compared to the exposure observed following single dose administration of 10 mg rizatriptan melt tablet to adults. The clinical relevance of these differences is unclear.

Hepatic impairment (Child-Pugh score 5-6):

Following oral administration in patients with hepatic impairment caused by mild alcoholic cirrhosis of the liver, plasma concentrations of rizatriptan were similar to those seen in young male and female subjects. A significant increase in AUC (50%) and C_max (25%) was observed in patients with moderate hepatic impairment (Child-Pugh score 7). Pharmacokinetics were not been studied in patients with Child-Pugh score> 7 (severe hepatic impairment).

Renal impairment:

In patients with renal impairment (creatinine clearance 10-60 ml / min per1.73 m²), the AUC of rizatriptan after tablet administration was not significantly different from that in healthy subjects. In hemodialysis patients (creatinine clearance <10 mL / min per 1.73 m²), the AUC for rizatriptan wasapproximately 44% greater than that in patients with normal renal function. The maximal plasma concentration for rizatriptan in patients with all degrees of renal impairment was similar to that in healthy subjects.

Preclinical data indicate no risk for humans based on conventional studies of repeat dose toxicity, genotoxicity, carcinogenic potential, reproductive and developmental toxicity, safety pharmacology and pharmacokinetics and metabolism.

Mannitol (E421)

Calcium silicate (E 552)

Crospovidone

Aspartame (E 951)

Peppermint flavor

Silica colloidal anhydrous

Sodium stearyl fumarate

Not applicable.

2 years.

Do not store above 30°C.

Blister pack consisting of Aluminium lidding material PAP/PET/AL and Aluminium forming material OPA/Alu/PVC consisting of 3, 6 and 18 orodispersible tablets.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Tillomed Laboratories Limited

220 Butterfield, Great Marlings

Luton, LU2 8DLUnited Kingdom

PL 11311/0547

25/08/2017

18/03/2020